Merck Is Benefiting From Keytruda, but Jim Cramer Prefers Eli Lilly
Merck vs. Eli Lilly.
TheStreet's Action Alerts PLUS said Merck (MRK) - Get Merck & Co., Inc. Report is benefiting from its Keytruda drug but Cramer prefers Eli Lilly (LLY) - Get Eli Lilly and Company Report , a holding of his charitable trust.
Watch all of Jim Cramer's latest videos, right here:
- Here Is Why Jim Cramer Doesn't Want to Buy More Starbucks Shares for Action Alerts PLUS
- Jim Cramer Reacts to Amazon's Big Quarterly Miss
- Jim Cramer Reacts to Chevron and Exxon Mobil Earnings
- Jim Cramer Reveals When to Buy Airline Stocks
Scroll to Continue
